Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1360 Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice
Compose a Response to This Article
Other responses
No responses have been published for this article.